SOLVHealthcare · Medical Instruments & SuppliesThe 15 Wall Street analysts covering Solventum Corp. hold a median 12-month price target of $95 — +9.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 17 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Solventum Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.
Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SOLV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.4% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | BTIG | Maintains | Buy | $91 → $95 |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | $93 → $102 |
| 6 Aug 2026 | Piper Sandler | Maintains | Overweight | $92 → $105 |
| 6 Aug 2026 | Stifel | Maintains | Buy | $90 → $100 |
| 6 Aug 2026 | UBS | Maintains | Buy | $95 → $101 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $94 → $101 |
| 28 July 2026 | UBS | Upgrade | Buy | $95 |
| 28 July 2026 | UBS | Upgrade | Buy | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 15 May 2026 | Wedbush | Initiates | Outperform | — |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 6 May 2026 | Keybanc | Maintains | Overweight | — |
| 6 May 2026 | Stifel | Maintains | Buy | — |
| 6 May 2026 | UBS | Maintains | Neutral | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 27 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Mar 2026 | Rothschild & Co | Initiates | Sell | — |
| 27 Feb 2026 | BTIG | Reiterates | Buy | — |
| 27 Feb 2026 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SOLV appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 56% of US stocks
Cheaper than 35% of US stocks
Cheaper than 19% of US stocks
Higher than 33% of US stocks
Higher than 39% of US stocks
Higher than 72% of US stocks
Higher than 63% of US stocks
Higher than 80% of US stocks
Higher than 89% of US stocks
Higher than 63% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Solventum Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted Solventum (SOLV) as a top value stock for the long term, referencing the Zacks Style Scores framework for identifying strong, market-beating stocks for investment portfolios.
Why it matters — The item flags SOLV as a value stock with long-term potential in a stock-selection framework, which a Solventum watcher would note as a positive signal.
Solventum plans to spin off its $1.4 billion Health Information Systems (HIS) business, a move that will sharpen its MedTech focus while giving HIS more flexibility to pursue growth.
Why it matters — SOLV watchers would care because the spinoff could reshape the company's portfolio by separating its HIS business from its MedTech operations.
Zacks Investment Research highlights Solventum (SOLV) as a strong momentum stock through its Zacks Style Scores feature, which helps investors identify strong stocks by style category.
Why it matters — Solventum watchers would care because the recognition as a strong momentum stock signals that it is being flagged as a standout within Zacks' screening methodology.
Solventum (NYSE: SOLV) reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover, and a tariff refund benefit. The company also announced plans to separate its Health Information Systems (HIS) business as part of a broader effort to sharpen its focus on medical technology markets.
Why it matters — A Solventum watcher would care because the company beat its internal expectations and is restructuring to sharpen its focus on medical technology through the planned separation of its HIS business.
Solventum's second-quarter earnings and revenues exceeded estimates, with organic sales rising 9.5%, leading the company to raise its 2026 guidance, partly due to ERP timing benefits.
Why it matters — The beat on quarterly results and upward revision to 2026 guidance signal stronger-than-expected operational performance and improved near-term outlook for Solventum.
The 15 Wall Street analysts covering Solventum Corp. have a median 12-month price target of $95, with estimates ranging from $70 to $113. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Solventum Corp., 8 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Solventum Corp. 89 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, Solventum Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +9.4% from the last close, and Ticker Nerd's factor model ranks Solventum Corp. 89 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Solventum Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $113 over the next 12 months.
Solventum Corp. returned +21.6% over the 12 months to 17 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Solventum Corporation is a global healthcare company that develops, manufactures, and commercializes a broad portfolio of medical technologies and solutions. Its primary focus is enabling better, smarter, safer healthcare across clinical settings by combining material science, data science, and digital capabilities.
The most recent item we track (Zacks Investment Research, 17 Aug 2026): "Why Solventum (SOLV) is a Top Value Stock for the Long-Term". Zacks Investment Research highlighted Solventum (SOLV) as a top value stock for the long term, referencing the Zacks Style Scores framework for identifying strong, market-beating stocks for investment portfolios.
Solventum Corporation is a global healthcare company that develops, manufactures, and commercializes a broad portfolio of medical technologies and solutions. Its primary focus is enabling better, smarter, safer healthcare across clinical settings by combining material science, data science, and digital capabilities. The company operates through four main business segments: MedSurg, which includes wound care, infection prevention, vascular access, and surgical solutions; Dental Solutions, offering dental materials, consumables, and orthodontic products; Health Information Systems, providing software and informatics for clinical documentation, coding, and revenue cycle workflows; and Purification and Filtration, supplying advanced filtration technologies used in bioprocessing and other high-specification applications. Solventum serves hospitals, clinics, dental practices, and biopharmaceutical and life sciences customers in numerous countries worldwide. Founded in 2023 and headquartered in Eagan, Minnesota, United States, Solventum plays a significant role in the healthcare market by delivering consumable products, capital equipment, and software-enabled solutions that support patient care and operational efficiency for healthcare providers.
CEO Mr. Bryan C. Hanson · 20,584 employees · United States · https://www.solventum.com